Frontier Biotechnology: Genome Editing, Advanced Therapies & AI-Driven Bioscience

A baby has been treated with a gene editor built for his mutation alone. An mRNA therapy designed around one patient's tumour has succeeded in a phase three trial. Proteins that never existed in nature are now designed by software, and a drug whose target and molecule both came from AI has produced peer-reviewed clinical data. This course covers the technologies behind those events and, just as importantly, how to judge what the evidence actually shows. You will work through precision genome editing, RNA and cell therapies, engineering biology and biomanufacturing, AI-driven bioscience, and the regulation, biosecurity and access questions that decide what reaches patients. Every module is taught through real cases from the UAE, the wider Gulf, India, the UK and beyond, including the first approved CRISPR therapy and its Gulf approvals, the first prime-editing patient, a gene-editing safety hold and its resolution, India's low-cost CAR-T, and national genomics and biomanufacturing programmes. Leader-level activities ask you to analyse multi-issue cases rather than recall definitions. The course explains how these technologies work and how they are governed. It does not teach laboratory protocols or clinical decisions.

Advanced therapies, genomics and AI-driven discovery are now funded national priorities across the UAE, Saudi Arabia and India, and the people in demand are those who can assess a technology rather than only run an assay. This course builds that judgement, and connects naturally to the PCR & Molecular Diagnostics, Laboratory Biosafety & Biosecurity and ISO/IEC 17025 SkillCerts.